Additional Relevant Details The results from this study have been published in the journal PLOS ONE(http://dx.doi.org/10.1371/journal.pone.0158156)."These data show that CVC displayed significant anti-inflammatory and anti-fibrotic effects across a range of in vivo models, including non-alcoholic steatohepatitis (NASH), liver and kidney fibrosis models. These findings support CVC's anti-inflammatory and anti-fibrotic mechanism of action, and are further substantiated by results from a diet-induced NASH model, where CVC-treated animals had significantly less liver fibrosis and decreased lobular inflammation and hepatocellular ballooning, the hallmark features of NASH, relative to untreated animals," said Scott Friedman, M.D., chief,Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, and lead author. "The comprehensive and consistent preclinical data demonstrating the potent anti-inflammatory and anti-fibrotic effects of CVC enabled its clinical development in patients with NASH and fibrosis.""We are excited about the publication of these translational data which substantiate CVC's potential to address a serious medical condition like fibrotic NASH. With the top-line primary analysis results of our Phase 2b CENTAUR study expected in the third quarter of 2016, this is a transformative time for Tobira as we continue to build our NASH program and prepare for Phase 3," said Eric Lefebvre, M.D., chief medical officer of Tobira.